Diurnal is now Neurocrine UK
- Products
Products
Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.
- Clinical Resources
Clinical Resources
Diurnal is dedicated to developing new treatments to aid lifelong treatment for rare and chronic endocrine conditions
- Transparency
Transparency
Diurnal is committed to transparency in its interactions. Diurnal commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency.
- Careers
Careers
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision. Visit this section to view our current opportunities.
- Awards
Awards
A limited number of awards is available each year, and all applications will be judged objectively by an independent panel.
Mission Statement
To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.
Overview
Neurocrine is committed to transparency in its interactions. Neurocrine commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency. Neurocrine has published details of its transfers of value required under the ABPI Code on the ABPI website and on this website. Disclosures prior to 2025 are reported under the legacy name Diurnal.